REGENERON CELL MEDICINES
Live / Allowed — Notice of allowance issued (as of 11 Nov 2025)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 04 Jul 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98625063
- Mark type
- Stylized text
- Filed
- 04 Jul 2024
- Published for opposition
- 16 Sept 2025
- Attorney of record
- Terrence J. McAllister
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and substances for the treatment of diseases, namely, genetic diseases, diseases of the immune system, infectious diseases, autoimmune diseases, and cancer; genetically modified cells, genome editing reagents and biological preparations, namely, viral vectors, all for the treatment of diseases, namely, genetic diseases, diseases of the immune system, infectious diseases, autoimmune diseases, and cancer
- Class 042 — Scientific and technological services: Pharmaceutical research and development services
Owner
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, US
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, US
Prosecution history
- 11 Nov 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 16 Sept 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 16 Sept 2025 — PUBLISHED FOR OPPOSITION
- 10 Sept 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 14 Aug 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 30 Jun 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 30 Jun 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 30 Jun 2025 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 21 Apr 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 21 Apr 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 21 Apr 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 29 Jan 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 29 Jan 2025 — NON-FINAL ACTION E-MAILED
- 29 Jan 2025 — NON-FINAL ACTION WRITTEN
- 16 Jan 2025 — ASSIGNED TO EXAMINER